{"entity":{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","aka":[],"tldr":"A phase 2 trial of JNJ-79635322, Tocilizumab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07589634 by Janssen Research & Development, LLC, with 230 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: Ramantamig, Tocilizumab, Placebo. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07589634","url":"https://clinicaltrials.gov/study/NCT07589634"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["monoclonal-antibody","t-cell-engager"],"targets":[],"drugs":["jnj-79635322","tocilizumab"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07589634","phase":"2","setting":"79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","started":"2026-06-30","startedType":"actual","enrolled":230,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07589634/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}